| Bioactivity | KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor 1 (S1P1 Receptor) (IC50=79.2 nM). KRO-105714 inhibits SPC-induced proliferation of NIH3T3 (IC50=5.6 nM), inhibits SPC-induced cell migration (IC50=0.59 μM) and tube formation in HUVECs. KRO-105714 inhibits SPC-induced generation of IL-4 and IL-5, exhibits anti-inflammtory efficacy in mouse atopic dermatitis models[1]. |
| CAS | 1137536-21-0 |
| Formula | C26H30N4O3S |
| Molar Mass | 478.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yoon SB, et al., A novel sphingosylphosphorylcholine and sphingosine-1-phosphate receptor 1 antagonist, KRO-105714, for alleviating atopic dermatitis. J Inflamm (Lond). 2020 May 29;17:20. |
KRO-105714
CAS: 1137536-21-0 F: C26H30N4O3S W: 478.61
KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.